FLUDEOXYGLUCOSE (18F) INJECTION SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

FLUDEOXYGLUCOSE 18F

Prieinama:

WINNIPEG REGIONAL HEALTH AUTHORITY

ATC kodas:

V09IX04

INN (Tarptautinis Pavadinimas):

FLUDEOXYGLUCOSE (18F)

Dozė:

0.5GBQ

Vaisto forma:

SOLUTION

Sudėtis:

FLUDEOXYGLUCOSE 18F 0.5GBQ

Vartojimo būdas:

INTRAVENOUS

Vienetai pakuotėje:

15G/50G

Recepto tipas:

Schedule C

Gydymo sritis:

ROENTGENOGRAPHY

Produkto santrauka:

Active ingredient group (AIG) number: 0152591009; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2012-11-06

Prekės savybės

Fludeoxyglucose (
18
F)
1
PRODUCT MONOGRAPH
TRADE NAME
Fludeoxyglucose (
18
F) Injection
Parenteral Solution, > 0.5 GBq/vial
Diagnostic Radiopharmaceutical
Winnipeg Regional Health Authority
The Great-West Life PET/CT Centre
Suite 751, 7th Floor
715 McDermot Avenue
Winnipeg, MB R3E 3P4
Date of
$XWKRUL]DWLRQ:
November 6, 2012
Control #: 153940
Fludeoxyglucose (
18
F)
2
TABLE OF CONTENTS
FLUDEOXYGLUCOSE (
18
F) INJECTION
...................................................................................................
3
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
DESCRIPTION
...............................................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
4
CONTRAINDICATIONS
..............................................................................................................
5
WARNINGS AND PRECAUTIONS
.............................................................................................
5
ADVERSE REACTIONS
...............................................................................................................
6
DRUG INTERACTIONS
...............................................................................................................
7
DOSAGE AND ADMINISTRATION
...........................................................................................
7
RADIATION DOSIMETRY
..........................................................................................................
9
OVERDOSAGE............................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
11
STORAGE AND STABILITY
.............